To identify E2 dependencies in AML, we utilized publicly available CRISPR/Cas9 screens and identified the ubiquitin conjugating enzyme E2 N–UBE2V1 (UBE2N-UBE2V1) complex among the top targets in AML. Here, UBE2N is linked to acute myeloid leukemia.